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 ABSTRACT 
 
 
OBJECTIVE: The objective of this selective EBM review is to determine if Suvorexant 
(Belsomra) is effective in reducing wakefulness after sleep onset in healthy patients diagnosed 
with insomnia that are 18 years old or older. 
 
STUDY DESIGN: Systematic review of three published, randomized controlled trials (double-
blind, placebo-controlled) between 2012-2014, all English.  
 
DATA SOURCES: Three randomized controlled trials published between 2012-2014 were found 
using PubMed. 
 
OUTCOMES MEASURED:  Polysymnography, psychomotor performance test, PSG 
measurements of sleep, visual scoring, efficacy assessed with an electronic diary, Sheehan 
Disability Scale, vitals, EKGs, PE, MVAV questionnaire, QIDS-SR to assess mood, Tyler 
Withdrawal Symptom Questionnaire 
 
RESULTS: The first study, Michelson et al proved that after one year, suvorexant showed 
greater reduction in wakefulness after sleep onset (WASO) than placebo with a change in 
baseline -33.5 (-37.4 to -29.7) compared to placebo, -23.8 (-29.3 to -18.3). Herring et al proved a 
reduction in WASO as well with a -33.2 (-46.3, -20.2) change in baseline compared to placebo. 
Sun et al showed a reduction in WASO with a suvorexant  95% CI (11.61, 18.12) vs placebo 
(16.61, 25.91).  
 
CONCLUSION: According to the three double-blind randomized controlled trials, Suvorexant 
(Belsomra) is effective in reducing wakefulness after sleep onset in healthy patients with 
insomnia over the age of 18 years old. 
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INTRODUCTION 
 Insomnia can be described as a condition in which an individual has difficulty falling 
asleep, staying asleep, waking throughout the night, and difficulty going back to sleeping after 
waking up 1. This paper evaluates three double blind, randomized, controlled trials comparing 
the efficacy of Suvorexant (Belsomra) in reducing wakefulness after sleep onset in healthy 
patients diagnosed with insomnia. Insomnia is diagnosed in about 15-25% of patients per year in 
which other sleep disorders have been studied and excluded 2.  The relevance of insomnia to 
Physician assistants is due to a rise in the need for healthcare. According to the Journal of Sleep 
Specialists healthcare related costs due to insomnia range from $30-35 billion à $92.5-$107.5 
billion/year. Such costs included that of medications, patient to physician encounters, office 
visits, and disability from the workplace 3. From 1999-2010 the amount of visits for insomnia 
ranged from 4.9 million to 5.5 million 4.  
 Insomnia is broken down into primary and secondary subtypes. We know that secondary 
is associated with chronic pain disorders, asthma, CHF, stroke, PTSD, depression, anxiety, 
caffeine and nicotine usage, etc. When other diseases have been ruled out, primary insomnia is 
the diagnosis. Because there is no known medical condition that causes insomnia, it is merely a 
diagnosis of exclusion 5.  Methods used to treat the condition vary from lifestyle changes, 
Cognitive-Behavioral Therapy, as well as to pharmacologic approaches. In most cases, these 
methods are used in conjunction with one another to achieve the best result for the patient. Such 
lifestyle changes include; avoiding caffeine, tobacco, stimulants, alcohol, making bedtime habits 
and schedules, and enduring daily exercise. Such pharmaceuticals used for the treatment of 
insomnia include; benzodiazepines, zolpidem, TCA’s, Trazadone, and melatonin 6.  
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 Although the above medications treat the symptoms of insomnia, Belsomra (Suvorexant) 
is an oral medication that specifically inhibits orexin. Orexin promotes wakefulness. So it is 
thought to have more success at treating the cause of insomnia than just the symptoms 7.  
OBJECTIVE 
 The objective of this review is to determine if suvorexant (Belsomra) is effective in 
reducing wakefulness after sleep onset in healthy patients diagnosed with insomnia 18 years old 
or older.    
METHODS 
 Three double-blind randomized controlled trials were analyzed within this review. The 
population of participants was limited to healthy patients without medical conditions, whose ages 
ranged from 18-65+ years old. Regarding interventions, each study provided their participants 
with suvorexant but what varied was the dosage given and the conditions in which the specific 
dose was given. Such interventions included; patients receiving nightly suvorexant (40mg if 
younger than 65 y.o., 30 mg if older than 65 y.o.), receiving nightly suvorexant (10, 50, or 
100mg), and patients receiving four different doses of suvorexant (10, 20, 40, 80mg) without age 
age discrimination. Comparisons were made between the treatment group receiving suvorexant 
and the control group receiving placebo. Outcomes measured included; tolerability, safety, sleep 
efficiency, wakefulness after sleep onset, duration of time from lights off to persistent sleep 
onset, morning residual effects, and improvement of subjective total sleep time.  
 The keywords used in this search were suvorexant, Belsomra, and Insomnia. These three 
randomized controlled trials were published between 2012-2014, in English, and were found 
using the PubMed database. Articles were chosen based on the relevance to the proposed 
question and patient oriented outcomes (POEMS). The inclusion criteria consisted of participants 
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who were healthy and between the ages of 18-65+ years old. The participants had to have a BMI 
<33 kg/m^2 and good health based on medical history and physical exam. Each individual 
needed to report a usual bedtime between 20:00-00:00, self-reported sleep duration >6.5h and 
<9h per night. They also needed to be diagnosed with primary insomnia based on DSM-IV-TR. 
Lastly, they needed to meet the polysymnography criteria of latency to persistent sleep (LTPS) 
of >20 minutes and mean wakefulness after sleep onset (WASO) of >60 minutes. Participants 
were excluded from the study if they were diagnosed with neurological disorders, psychotic 
illness, substance abuse, or had an unstable medical disorder. Participants could not be shift 
workers, nor could they take any other medications during the study. During the experiment, no 
patient was permitted to travel across more than three time zones. Summary of statistics reported 
for treatment efficacy included; 95% CI, p-values, and change from baseline. Safety statistics 
included RRI, ARI, and NNH. Table 1 summarizes the demographics of each study.  
Table 1: Demographics & Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Michelson  
20148 
Double 
Blind 
RCT 
781 18 
years 
or 
older 
 Diagnosis of 
insomnia via 
DSM-IV-TR 
neurological 
disorders, 
psychotic 
illness, 
substance 
abuse 
311 40 mg for <65 
years of age, 30 
mg for patients 
>65 years of age 
Herring 
20129 
Double 
Blind 
RCT 
254  18-64 
years 
old 
physical and 
mental health, 
LTPS  >20 
minutes, avg 
WASO >60 min. 
None stated 26 assess 4 doses of 
suvorexant (10, 
20, 40, 80 mg) 
Sun 
201310 
Double 
Blind 
RCT 
22  18-45 
years 
old  
Healthy men, BMI 
<33 kg/m^2, 
bedtime  20:00-
00:00, >6.5h and 
<9h sleep per night  
No shift 
work, no >3 
time zones, 
no other 
meds during 
study 
3 Periods 1-4: 10 
mg, 50 mg, and 
100mg; Period 5: 
10, 50, or 100 
mg 
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OUTCOMES MEASURED 
 Each study’s outcomes consisted of POEMS and were measured in various ways 
depending on the nature of the study. The purpose of this review is to compare the results of 
wakefulness after sleep onset from each study. In Michelson et al, participants received 
suvorexant every night for one year 8. Patients were placed into either a placebo group or 
suvorexant group based off an “allocation-schedule system” 8. They were placed into their 
groups according to age and geographical location. The nightly doses included; 40 mg for 
patients younger than 65 years of age and 30 mg for patients >65 years of age 8. During the year 
there was a “2-month randomized discontinuation phase” 8. During the discontinuation phase, 
certain participants who were assigned suvorexant continued taking it or they were substituted 
suvorexant for placebo. Those in the placebo group did not stop taking placebo. At months 1, 3, 
6, 9, 12, 13, and 14, the participants had to return to an assigned clinic to log their experiences. 
Safety assessments were evaluated via an open ended questionnarie for adverse events; Motor 
Vehicle Accidents and Violations (MVAV) questionnaire. Mood throughout the study was 
evaluated via the The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR). 
Efficacy was evaluated with a sleep diary. In the diary patients logged their Total Sleep Time 
(sTST), Time to Sleep Onset (sTSO), wake after sleep onset (WASO), number of awakenings 
(NAW), quality of sleep (QUAL), and refreshed on waking (FRESH) 8.  
 In Herring et al four nightly doses (10, 20, 40, and 80mg) of suvorexant were evaluated 
amongst the participants. The study consisted of four trials that consisted of two periods each 
with a specific dose of the drug. In each trial, the participant received a different dose than before 
9 . Participants were again randomized with a “computer-generated randomized allocation 
schedule” 9. Participants were chosen from twenty-nine sites in the U.S. and twelve sites from 
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Japan. To evaluate efficacy, polysmynography (PSG) was performed to measure the quality of 
sleep of the participants a few times a month. Patients were assessed for eight hours during PSG. 
Efficacy was also evaluated by the participants via electronic patient diaries every night. They 
had to complete a morning questionnaire regarding sleep from the night before and an “evening 
questionnaire to assess daytime function”9. The Insomnia Severity Index and Sheehan Disability 
Scale were also used. Safety of suvorexant was evaluated via vital signs, EKGs, physical exam, 
and blood work. “The Digit Symbol Substitution Test (DSST) and Digit Symbol Copying Test 
(DSCT) were performed on the morning after PSG nights” to evaluate psychomotor effects 9. 
Those who dropped out of the study or were placed on placebo during the discontinuation phase 
were given the Tyrer Withdrawal Symptom Questionnarire to assess withdrawal symptoms 9.  
 Sun et al assessed the efficacy of suvorexant in a five period study. Participants were 
chosen based on the inclusion in table 1 as well as the same scheduling system in the first two 
studies. During the first four periods, participants received a dose of 10, 50, 100mg, and placebo 
in a varied order. For each of the four periods patients had to be assessed with PSG for two 8 
hour sessions. PSG was used to measure LPS, WASO, QUAL, and TST and also time in each 
stage of sleep. Stages of sleep included;	REM, NREM, SWS and Stages 1, 2, 3, and 4 10. “Next-
day residual effects were assessed with psychomotor performance and subjective measurements 
in the morning”10. Simple reaction time, choice reaction time, and digit symbol substitution tests 
were used to assess one’s psychomotor performance in the morning 10. The Leeds Sleep 
Evaluation Questionnaire was used by participants every morning to evaluate the amount and 
nature of their awakenings 10. The purpose of period five was to assess the pharmacodynamics of 
suvorexant. This time participants only received one of the four doses and spent the night for 
Hart, Suvorexant (Belsomra) and Insomnia  6 
evaluation. Blood was drawn at eleven intervals after the dose was given. Safety was once again 
assessed via vital signs, physical exam, EKGs and laboratory work ups 10. 
RESULTS 
 Each of the three double-blind randomized controlled trials compared patients with 
insomnia taking placebo to those taking suvorexant. Each study gave their participants different 
doses of suvorexant but still studied the same parameters. In Michelson et al, healthy participants 
were all older than eighteen years. Those who were > 65 years old received 30 mg of Suvorexant 
nightly while participants <65 years old received 40mg of Suvorexant. In the discontinuation 
phase, some were switched to placebo while others remained on Suvorexant. The purpose of 
discontinuation was to analyze any possible withdrawal effects 8. Although these participants 
differed in age, they were all placed into the same group and compared to placebo. 
The purpose of this review was to analyze the effectiveness of suvorexant on wakefulness 
after sleep onset (WASO). In addition to that, the recurrence of the most common side effect, 
daytime somnolence was analyzed. There were 781 patients enrolled and 311 withdrew either 
due to adverse events, no follow up with physician, violation of treatment, or lack of efficacy. 
The data reported is continuous and could not be converted to dichotomous due to lack of 
information from the study.  At baseline, those in the suvorexant group reported an average 
WASO 80.1 (57.2) min. The placebo group reported a baseline WASO at 71.4 (56.1) min. After 
a year of treatment the change from baseline was -33.5 (-37.4 to -29.7) min for those taking 
suvorexant. Placebo group’s change from baseline was -23.8 (-29.3 to -18.3) min. The p-value of 
<.0048 proves that this dose was efficacious in reducing WASO. After one year of treatment, the 
somnolence rate was 69/521 (13.2) enrolled in suvorexant and 7/258 (2.7) in placebo. NNH was 
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10, so for every 10 patients treated one patient experienced somnolence. The safety data 
calculated was dichotomous8. 
Table 2: Michelson et al Suvorexant v Placebo Treatment Efficacy for WASO 
Type of Study Baseline 
WASO (min) 
Change from Baseline WASO (min) 
Suvorexant (30 
mg, 40mg) 
80.1 (57.2) -33.5 (-37.4 to -29.7) 
Placebo 71.4 (56.1) -23.8 (-29.3 to -18.3) 
 
Table 3: Michelson et al Suvorexant v Placebo Occurrence of Somnolence 
Type of Study Number of participants with 
somnolence 
Suvorexant (30mg, 40mg) 69/521 (13.2) 
Placebo 7/258 (2.7) 
 
Table 4: Michelson et al Suvorexant v Placebo Treatment Safety (somnolence) 
	
Patients	with	Somnolence	after	
treatment		
Relative	risk	
increase	(RRI)	
Absolute	risk	
increase	(ARI)	
Number	needed	
to	harm	(NNH)	
CER	
(control	event	
rate)	
EER	
(experimental	
event	rate)	
EER-	CER	
CER	
EER	-	CER	 1/ARI	
.03	 .13	 3.34	 .10	 10	
 
Herring et al studied participants that were both healthy men and women ages 18-64 
years old. The intervention within this study was to administer one of four doses of suvorexant to 
each participant within a given period. There were four trials and each trial consisted of two 
periods. The doses administered during each trial were 10, 20, 40, and 80 mg. The data for 
efficacy was based off the 40 mg dose 9. Unlike Michelson et al, age did not determine which 
dose was given; it was randomized. During each trial there was a one week period during which 
the individuals received placebo. So, the patients receiving suvorexant would eventually 
compare the effects to that of placebo to themselves. The study originally had 254 participants 
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and 26 withdrew due to withdrawal, pregnancy, adverse events, physician decision, lack of 
efficacy, and violation of treatment regimen9.  
The data collected for treatment efficacy of WASO was continuous based on the 40 mg 
dose and could not be converted to dichotomous due to lack of information from the study. The 
baseline WASO for those taking the 40mg dose was 107.3 (57.6) min., compared to the placebo 
group, the baseline WASO was 100.7 (45.1) min. After a four week study, the change from 
baseline for those taking 40 mg versus placebo was -33.2 (-46.3, -20.2) min. The P-value was 
<.001, which showed that this dose was efficacious in reducing WASO9. Recurrence rate for 
somnolence as an adverse effect was analyzed; which presented as dichotomous data. For those 
taking 40 mg of suvorexant, 6/59 (10.2) participants reported somnolence compared to placebo 
who reported 1/249 (.4) 9. NNH was 11, therefore eleven patients need to be treated before one 
experienced somnolence compared to placebo 
Table 5: Herring et al Suvorexant v Placebo Treatment Efficacy for WASO 
Type of Study Baseline WASO (min) Change from Baseline 
WASO (min) Suvorexant v 
Placebo 
Suvorexant (40mg) 107.3 (57.6) -33.2 (-46.3, -20.2) 
Placebo 100.7 (45.1)  
 
Table 6: Herring et al Suvorexant v Placebo Occurrence of Somnolence  
Type Study Number of participants with 
somnolence 
Suvorexant (40 mg) 6/59 (10.2) 
Placebo 1/249 (0.4) 
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Table 7: Herring et al Suvorexant v Placebo Treatment Safety 
Patients	with	Somnolence	After	
Treatment	
	
Relative	risk	
increase	(RRI)	
Absolute	risk	
increase	(ARI)	
Number	needed	
to	harm	(NNH)	
CER	(control)	 EER	(experimental)	 EER-	CER	
CER	
EER	-	CER	 1/ARI	
.004	 .102	 .961	 .098	 11	
 
Sun et al studied healthy men between 18 and 45 years of age. The intervention of the 
study was broken into five periods. During the first four periods the participants received either 
placebo, 10, 50, and 100 mg. During period five, the participants received one of the four doses 
or placebo. The doses were given nightly one hour prior to polysymnography 10. The data for 
efficacy was based on the 50mg dose and the dose that each participant received was 
randomized. Twenty-two participants originally enrolled in the study and nineteen completed. 
Two participants discontinued due to the use of illicit drugs and another discontinued because 
they violated the inclusion criteria by taking other medications during the study 10. 
 The data collected for treatment efficacy of WASO was continuous based on the 50 mg 
dose and could not be converted into dichotomous data. The original baseline values weren’t 
given, only change in baseline for placebo and the 50 mg dose. When the study concluded, the 
ending WASO recorded by 50 mg participants was 15.93 min with a 95% CI of (11.61, 18.12). 
Such values demonstrated a significant reduction in WASO compared to placebo. WASO 
recorded by placebo was 22.75 min with a 95% CI (16.61, 25.91).  After treatment with either 50 
mg or placebo; 0/20 participants reported somnolence in placebo while 1/10 (4.5) participants 
reported while taking 50 mg 10. Safety data reported as dichotomous. NNH was 21, therefore 21 
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participants would be treated before one participant experienced somnolence following treatment 
compared to control. 
Table 8: Sun et al Suvorexant v Placebo Treatment Efficacy for WASO 
Study WASO post 
treatment (min) 
Change from Baseline 
WASO (min) 
Suvorexant 50 mg 15.93 (11.61, 18.12) 
Placebo 22.75 (16.61, 25.91) 
 
Table 9: Sun et al Suvorexant v Placebo Occurrence with Somnolence 
Study Number of participants with 
somnolence  
Suvorexant 50 mg 0/20 
Placebo 1/10 (4.5) 
 
Table 10: Sun et al Suvorexant v Placebo Treatment Safety (Somnolence) 
Patients	with	Somnolence	After	
Treatment	
	
Relative	risk	
increase	(RRI)	
Absolute	risk	
increase	(ARI)	
Number	needed	to	
harm	(NNH)	
CER	 EER	 EER-	CER	
CER	
EER	-	CER	 1/ARI	
0	 .048	 N/A	 .048	 21	
 
DISCUSSION  
According to the results, all three studies successfully proved that suvorexant (Belsomra) 
decreased wakefulness after sleep onset (WASO) 8,9,10. Michelson et al had a relatively large 
participant population but as stated in the study, the purpose of a large participant population was 
to prepare for drop outs 8. In Michelson et al, they based their study on a population of about 100 
participants, so by enrolling 781 people originally, they were able to gain the data they wanted 
with the drop out rate they obtained.  In Michelson et al, the set back they faced was that their 
adverse effect data may not have been sufficient enough because they only monitored one year 
of treatment 8. In addition to that, Michelson et al did not record their participants’ behavior the 
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day after treatment nor did they ask about the patient’s day to day function during treatment 8. 
Due to the neglect of these factors, adverse effects may not have been as accurate as they could 
have been. Also, unlike Herring and Sun et al, Michelson et al combined the results from both 
doses into one large result. So, this study doesn’t state which dose is more effective than the 
other 8. 
The main limitation seen in Herring and Sun et al, was their minimal participant 
population and the lack of elderly individuals within the study9,10. According to Herring et al, 
insomniacs are primarily people over the age of 65, so not studying them may limit data 
regarding the efficacy in treatment. In addition to that, Herring et al only lasted for four weeks 9. 
So, it is possible that certain adverse effects may not have been apparent with conclusion of this 
study and it may not have been enough time for patients to see a positive result 9. Patients should 
be aware that Suvorexant (Belsomra) is a controlled substance (C-IV), has the ability to misused, 
and can lead to dependence 11. Belsomra is also contraindicated in those with narcolepsy11. 
According to Herring et al, neuron degeneration has been noted in patients taking Belsomra with 
narcolepsy. Because this drug is an antagonist to orexin, it can worsen symptoms in those with 
narcolepsy 9.  
CONCLUSION  
According to the data collected, Suvorexant (Belsomra) is effective in reducing WASO in 
healthy patients with insomnia over the age of 18 years old 8,9,10. Michelson et al had the perfect 
sample size and therefore each study should have a large participant pool. In addition to that, 
studies should extend for one year or more in order to gain a better outlook on the possible 
adverse effects, how long they last, and also the length of time necessary to experience positive 
effect. 
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